BIO
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

1,001
Mkt Cap
$7.61B
Volume
276,869.00
52W High
$343.12
52W Low
$211.43
PE Ratio
10.00
BIO Fundamentals
Price
$269.85
Prev Close
$279.03
Open
$275.96
50D MA
$297.14
Beta
0.88
Avg. Volume
321,003.35
EPS (Annual)
$27.85
P/B
1.01
Rev/Employee
$346,738.26
$8,108.47
Loading...
Loading...
News
all
press releases
TD Asset Management Inc Purchases 7,386 Shares of Bio-Rad Laboratories, Inc. $BIO
TD Asset Management Inc increased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 461.0% in the 3rd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Bio-Rad Laboratories, Inc. $BIO Shares Bought by GW&K Investment Management LLC
GW&K Investment Management LLC raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 24.9% during the 3rd quarter, according to its most recent disclosure with the Securities...
MarketBeat·2d ago
News Placeholder
Teachers Retirement System of The State of Kentucky Has $10.22 Million Stake in Bio-Rad Laboratories, Inc. $BIO
Teachers Retirement System of The State of Kentucky grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 36.8% in the third quarter, according to the company in its...
MarketBeat·2d ago
News Placeholder
Analysts Issue Forecasts for BIO FY2028 Earnings
Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Investment analysts at Zacks Research issued their FY2028 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a report...
MarketBeat·3d ago
News Placeholder
Roubaix Capital LLC Buys Shares of 8,112 Bio-Rad Laboratories, Inc. $BIO
Roubaix Capital LLC purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·4d ago
News Placeholder
Zacks Research Has Bearish Estimate for BIO Q1 Earnings
Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Investment analysts at Zacks Research cut their Q1 2026 earnings per share estimates for shares of Bio-Rad Laboratories in a report issued on...
MarketBeat·4d ago
News Placeholder
Artisan Partners Limited Partnership Has $24.22 Million Position in Bio-Rad Laboratories, Inc. $BIO
Artisan Partners Limited Partnership cut its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 26.9% in the third quarter, according to the company in its most recent filing with the...
MarketBeat·6d ago
News Placeholder
Bio-Rad Laboratories, Inc. $BIO Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. lowered its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned...
MarketBeat·9d ago
News Placeholder
Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving Average - Time to Sell?
Bio-Rad Laboratories (NYSE:BIO.B) Stock Price Crosses Below 200-Day Moving Average - Should You Sell...
MarketBeat·14d ago
News Placeholder
International Markets and Bio-Rad (BIO): A Deep Dive for Investors
Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Zacks·14d ago
<
1
2
...
>

Latest BIO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.